ArticleScientific reports2025
Animal-free alternatives for Matrigel in human iPSC-derived blood vessel organoid culture.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- From monolayer to organoids and multi-organ microphysiological systems: advancing regenerative medicine and precision therapies.Stem cell research & therapy · 2026Review
- New Frontiers of Drug Development Through the Use of New Approach Methodologies.The AAPS journal · 2026Review
- Animal-origin-free method for generating blood vessel organoids.Scientific reports · 2026Article
- Animal-free matrix alternative for three-dimensionalFrontiers in toxicology · 2026Article
- Patient-derived organoids in functional precision oncology: from experimental models to clinical decision-making.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The use of blood vessel organoids (BVOs), or vascular organoids derived from human induced pluripotent stem cells (hiPSC), provides a valuable tool for research on vascular regeneration. Vascular organoid culture relies on the use of Matrigel, a murine sarcoma-derived matrix, which limits its translational potential and reproducibility. This study evaluated the potential alternatives to Matrigel for both 2D hiPSC and 3D vascular organoid culture to enhance the clinical applicability of hiPSC-derived vascular organoids. Vitronectin is a suitable replacement for Matrigel in hiPSC culture and expansion, maintaining pluripotency and facilitating subsequent differentiation into vascular organoids. Additionally, we demonstrated that fibrin-based hydrogels effectively support vascular organoid differentiation, promoting vascular network formation and endothelial cell sprouting comparable to Matrigel-based cultures. Through gene expression analysis, surface area quantification, and immunohistochemistry, we validated the efficacy of Vitronectin and fibrin in supporting hiPSC-derived vascular organoid differentiation. This Matrigel-free protocol not only enhances reproducibility but is a step forward in xeno-free culture conditions, offering a versatile platform for disease modelling, vascular tissue engineering, and patient-specific therapeutic screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.